Drug Design Defect Litigation Faces Its Demise

Law360 (December 5, 2018, 2:01 PM EST) -- "The Demise of Drug Design Litigation: Death by Federal Preemption" is the intriguing title of the latest law review article written by the “Rabbi of Torts,” Prof. Aaron Twerski (we’re not making this up — Twerski’s Wikipedia page is the fifth result when we just Googled that phrase). Twerski, one of the American Law Institute’s reporters for the Restatement (Third) of Torts: Products Liability, has probably spilled as much ink as anyone in making sense of Restatement (Second) of Torts Section 402A, comment k (1965), one of the more opaque parts of the venerable Section 402A.

Indeed, in a prior article,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!